Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) shares crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $12.00 and traded as low as $10.50. Benitec Biopharma shares last traded at $11.12, with a volume of 202,427 shares changing hands.

Wall Street Analysts Forecast Growth

BNTC has been the topic of several research analyst reports. Wall Street Zen downgraded shares of Benitec Biopharma from a "hold" rating to a "sell" rating in a report on Saturday, February 14th. TD Cowen reiterated a "buy" rating on shares of Benitec Biopharma in a research note on Monday, January 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Benitec Biopharma in a report on Wednesday, January 21st. Zacks Research raised Benitec Biopharma from a "strong sell" rating to a "hold" rating in a report on Friday, November 14th. Finally, HC Wainwright set a $32.00 target price on Benitec Biopharma and gave the stock a "buy" rating in a research report on Monday, November 24th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $27.67.

View Our Latest Stock Analysis on Benitec Biopharma

Benitec Biopharma Stock Up 3.7%

The stock's 50 day moving average is $12.00 and its 200-day moving average is $13.14. The company has a market cap of $381.97 million, a PE ratio of -9.75 and a beta of 0.26.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last posted its earnings results on Thursday, February 12th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.03). On average, analysts anticipate that Benitec Biopharma Limited will post -1.48 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Suvretta Capital Management, L acquired 77,387 shares of Benitec Biopharma stock in a transaction on Monday, December 29th. The shares were bought at an average cost of $13.44 per share, with a total value of $1,040,081.28. Following the completion of the purchase, the director directly owned 9,700,195 shares of the company's stock, valued at $130,370,620.80. The trade was a 0.80% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders purchased 190,364 shares of company stock worth $2,442,105 over the last quarter. Insiders own 4.80% of the company's stock.

Hedge Funds Weigh In On Benitec Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of BNTC. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Benitec Biopharma during the 2nd quarter valued at approximately $38,000. BNP Paribas Financial Markets boosted its stake in Benitec Biopharma by 44.5% during the third quarter. BNP Paribas Financial Markets now owns 2,937 shares of the biotechnology company's stock worth $41,000 after buying an additional 904 shares during the period. Truvestments Capital LLC increased its position in Benitec Biopharma by 156.5% during the fourth quarter. Truvestments Capital LLC now owns 3,834 shares of the biotechnology company's stock valued at $52,000 after acquiring an additional 2,339 shares during the last quarter. Russell Investments Group Ltd. bought a new position in Benitec Biopharma during the third quarter valued at $79,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Benitec Biopharma in the second quarter valued at $80,000. Hedge funds and other institutional investors own 52.19% of the company's stock.

About Benitec Biopharma

(Get Free Report)

Benitec Biopharma Ltd NASDAQ: BNTC is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company's proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec's lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.

Featured Stories

• Five stocks we like better than Benitec Biopharma
• The gold chart Wall Street is terrified of…
• America’s 1776 happening again
• Buy this Gold Stock Before May 2026
• This makes me furious
• What a Former CIA Agent Knows About the Coming Collapse

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Benitec Biopharma Right Now?

Before you consider Benitec Biopharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.

While Benitec Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here